Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 19/20 | 1.00 |
| ▸ | MMP3 | P08254 | 18/20 | 1.00 |
| ▸ | MMP8 | P22894 | 16/20 | 1.00 |
| ▸ | MMP2 | P08253 | 16/20 | 1.00 |
| ▸ | MMP1 | P03956 | 16/20 | 1.00 |
| ▸ | MMP9 | P14780 | 15/20 | 1.00 |
| ▸ | MMP7 | P09237 | 14/20 | 1.00 |
| ▸ | BMP1 | P13497 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6290459 | 0.90 | MMP13 (0.82) | MMP13MMP3MMP8MMP2MMP1 | |
| SCHEMBL6294166 | 0.90 | MMP13 (0.88) | MMP13MMP3MMP8MMP2MMP1 | |
| SCHEMBL6291161 | 0.89 | MMP13 (1.00) | MMP13MMP3MMP8MMP2MMP1 | |
| SCHEMBL6289775 | 0.87 | MMP13 (0.89) | MMP13MMP3MMP8MMP2MMP1 | |
| SCHEMBL6291020 | 0.86 | MMP13 (0.84) | MMP13MMP3MMP8MMP2MMP1 | |
| SCHEMBL6293830 | 0.86 | MMP13 (0.86) | MMP13MMP3MMP8MMP2MMP1 | |
| SCHEMBL3250278 | 0.85 | MMP13 (0.74) | MMP13MMP3MMP8MMP2MMP1 | |
| SCHEMBL6293753 | 0.82 | MMP8 (0.73) | MMP13MMP3MMP8MMP2MMP1 | |
| SCHEMBL6289764 | 0.82 | MMP13 (1.00) | MMP13MMP3MMP8MMP2MMP1 | |
| SCHEMBL6293833 | 0.82 | MMP13 (1.00) | MMP13MMP3MMP8MMP2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6949545-B2 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY (US) | 2005-09-27 | — | — | US | claimed |
| US-20030139414-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-07-24 | — | — | US | claimed |
| US-8847003-B2 | Role of proteoglycans in drug dependence | SANNA PIETRO P (US) | 2014-09-30 | — | — | US | disclosed |
| US-8847003-B2 | Role of proteoglycans in drug dependence | SANNA PIETRO P (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140173764-A9 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2014-06-19 | — | — | US | disclosed |
| US-20140173764-A9 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2014-06-19 | — | — | US | disclosed |
| US-20120174240-A1 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120174240-A1 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | SANNA PIETRO P (US) | 2012-07-05 | — | — | US | disclosed |
| US-8119854-B2 | Role of proteoglycans in drug dependence | Sanna, Pietro P. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119854-B2 | Role of proteoglycans in drug dependence | Sanna, Pietro P. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100199361-A1 | Role of Proteoglycans in Drug Dependence | Sanna, Pietro Paolo (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100199361-A1 | Role of Proteoglycans in Drug Dependence | Sanna, Pietro Paolo (US) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139414-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | MME, MMP2, MMP9 | MMP13 38/4885MMP3 13/4885MMP8 37/4885 |
| US-20140173764-A9 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | OGFR, CSGALNACT1, OPRL1 | MMP13 544/4885MMP3 233/4885MMP8 626/4885 |
| US-20120174240-A1 | ROLE OF PROTEOGLYCANS IN DRUG DEPENDENCE | OGFR, CSGALNACT1, OPRL1 | MMP13 544/4885MMP3 233/4885MMP8 626/4885 |
| US-20100199361-A1 | Role of Proteoglycans in Drug Dependence | OGFR, CSGALNACT1, OPRL1 | MMP13 544/4885MMP3 233/4885MMP8 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.